Abstract
Adverse socioeconomic circumstances negatively affect the functioning of biological systems, but the underlying mechanisms remain only partially understood. Here, we explore the associations between life-course socioeconomic factors and four markers of epigenetic aging in a population-based setting.
We used data from a population-based study conducted in Switzerland (SKIPOGH) to assess the association between childhood, adulthood, and life-course socioeconomic indicators, and blood-derived markers of epigenetic aging (Levine’s, DunedinPoAm38, GrimAge epigenetic age acceleration (EAA) and the mortality risk score (MS)). We used mixed regression to explore the associations between socioeconomic indicators and markers of epigenetic aging independently, and counterfactual mediation to investigate the mechanisms underlying the life-course socioeconomic gradient in epigenetic aging.
Individuals reporting a low father’s occupation, adverse financial conditions in childhood, a low income, having financial difficulties, or experiencing unfavorable socioeconomic trajectories were epigenetically older than their more advantaged counterparts. Specifically, this corresponded to an average increase of 1.0-1.5 years for Levine’s epigenetic age when compared to chronological age, 1.1-1.5 additional years for GrimAge, 5%-8% higher DunedinPoAm38 EAA, and 2%-5% higher MS score. By exploring the life-course mechanisms underlying the socioeconomic gradient in epigenetic aging, we found that both childhood and adulthood socioeconomic factors contributed to epigenetic aging, and that detrimental lifestyle factors mediated the relation between socioeconomic circumstances in adulthood and EAA.
Our study provides novel empirical evidence for a “sensitive-period” life-course model, whereby adverse socioeconomic circumstances in childhood and adulthood negatively affected epigenetic aging. Counterfactual mediation analyses further showed that the effect of socioeconomic factors in adulthood operated through detrimental lifestyle factors, whereas associations involving early-life socioeconomic factors were less clear.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Lifepath project, which is funded by the European commission (Horizon 2020 grant 633666), the Swiss state secretariat for education, research and innovation (SERI), the Swiss National Science Foundation, the Medical Research Council and the Portuguese Foundation for Science. Silvia Stringhini was supported by the Ambizione PROSPER grant (Grant PZ00P3 147998) from the Swiss National Science Foundation. Dusan Petrovic was supported by the Doc.Mobility grant (Grant P1LAP3 178061) from the Swiss National Science Foundation. The SKIPOGH study is funded by a grant from the Swiss National Science Foundation (Grant 140331) and by intramural support of Lausanne, Geneva, and Bern University Hospitals. The funders hand no role in study design, data collection and analysis, manuscript writing, and in the decision to submit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Geneva University Hospitals gave ethical approval for this work Ethics committee of the Lausanne University Hospital gave ethical approval for this work Ethics committee of the Bern University Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint last authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
10 List of abbreviations
- BMI
- Body mass index
- CI
- Confidence interval
- CpG
- Cytosine-phospho-Guanine dinucleotide
- DAG
- Directed acyclic graph
- DNA
- Deoxyribonucleic acid
- DNAmPhenoAge
- Second generation phenotypic DNA methylation epigenetic clock (Levine)
- DunedinPoAm
- Second generation Dunedin Pace of Aging Methylation epigenetic clock
- EAA
- Epigenetic age acceleration
- GrimAge
- Second generation GrimAge epigenetic clock
- MS
- Mortality risk score
- MTE
- Marginal total effect
- NDE
- Natural direct effect
- NIE
- Natural indirect effect
- OR
- Odds ratio
- PM
- Proportion mediated
- SD
- Standard deviation
- SE
- Socioeconomic (factors)
- SKIPOGH
- Swiss Kidney Project on Genes in Hypertension
- WBC
- White blood cells
